ENCAPSULATED RETINOL:
WHAT THE PUBLISHED DATA MEASURED
Three double-blind, controlled trials. 154 human subjects. Skin samples, digital image analysis, instrument readings. No anecdotes. No marketing claims. Only what was measured. Vector ONE carries it at 0.3%, encapsulated, in a night cream.
What Actually Ages Your Skin. And Exactly Where Retinol Steps In.
Sunlight drives most visible ageing, and the chain is simple enough. UV light floods the skin with free radicals, and the balance tips the wrong way: skin breaks down more of its own collagen than it lays down, and the signal to rebuild quietens at the same time.
The damage hits from two sides at once. Collagen breaks down faster than the skin rebuilds it. That is not just a surface issue. It shows up as a measurable state: fragmented collagen fibres, less springy elastin, and skin that looks thinner and slacker than it did.
Retinol is not the active form, and that is the point. Skin converts it in two steps, and it can only do that so fast. The rate limit is not a flaw: it is a built-in slow release that hands skin a small, steady amount instead of a flood, which is why the published work records far less redness and irritation for retinol than for the stronger prescription form at matched concentrations. What the studies measured on the other side of that conversion is more newly formed collagen in skin samples and thicker epidermis.
52 Weeks. No Plateau. The Study Numbers Kept Climbing.
Most retinoid studies end at 12 weeks, capturing only the opening phase. Randhawa et al. ran two concurrent 52-week double-blind, vehicle-controlled trials on 62 subjects with mild to moderate sun-damaged skin. The active arm applied 0.1% stabilised retinol daily. Outcomes were confirmed by skin samples taken at week 52.
The week-52 samples suggested new skin cells were still forming after a full year of continuous use. Improvements kept going past week 12, with substantial gains appearing between weeks 12 and 52, exactly the stretch most studies never measure. Rebuilding below the surface is slow and expensive for the body. It rewards patience.
84% reduction in pigmentation. 44% reduction in entrenched wrinkles. Not at week 4. At week 52. With 0.1% stabilized retinol. The data says: consistency beats concentration.
Synthesis. Randhawa et al., 2015Head To Head Against The Prescription Comparator.
For decades the prescription form was assumed to be categorically superior. Draelos and Peterson tested that assumption directly. They compared a step-up retinol protocol against escalating doses of prescription tretinoin in 45 sun-damaged women (Fitzpatrick types I-IV). Retinol was layered with a lipid-infused moisturizer. Outcomes included grading by the study team, TEWL readings, and skin samples taken at week 12.
Protocol: Retinol escalated 0.25% to 0.5% to 1.0%. Tretinoin escalated 0.025% to 0.05% to 0.1%.
| Visual skin smoothness (retinol superior at week 4) | P = 0.031 |
| Subject-assessed skin softness (retinol superior)* | P = 0.006 |
| Crow's feet improvement (retinol superior)* | P = 0.001 |
| Dyschromia improvement (retinol superior)* | P = 0.004 |
| Skin dryness reduction (retinol arm only) | P < 0.001 |
* P-values sourced from full-text results tables. Rows without asterisk confirmed in published abstract.
Skin SamplesThe week-12 skin samples showed greater epidermal thickening and more newly formed collagen in the retinol subjects than in the tretinoin subjects. Both groups showed comparable TEWL readings at week 12. Skin dryness, however, was significantly reduced in the retinol arm (P < 0.001), an improvement not seen in the tretinoin group.
The slow conversion is not a weakness, it is the reason this works. Skin turns retinol into its active form at its own pace, so what it gets is a small, self-calibrated amount rather than the lot at once. The prescription form skips that step entirely. In this study that showed up exactly where you would expect: dryness and barrier stress on that side, and not on the retinol side.
Measured In The Skin, Not Just On It
Kong et al. combined skin-sample analysis with digital image-based wrinkle analysis and confocal microscopy on living skin. The question was whether retinol's visible improvements reflect real structural change or just surface hydration. They compared 0.1% retinol against 0.1% retinoic acid at matched concentrations.
Both retinol and retinoic acid significantly increased the collagen the skin was laying down, showing up in the samples as more newly formed collagen protein of both main types. The wrinkle score reduction at 4 weeks lined up with what the samples showed, which is what separates a structural change from a surface one.
Retinol produced the same changes in the skin and in the samples as retinoic acid did, and did it with significantly less redness and irritation. The slow conversion is why: skin sets the pace, so tolerability comes built in.
The Concentration Arms Race Is a Losing Strategy
The skincare market wants you to believe that 1.0% retinol is five times better than 0.2%. The published data says otherwise. A controlled comparison between 0.3% and 1.0% retinol (Mellody et al., Int J Cosmet Sci, 2022) found the two concentrations comparable on the measures taken: new cell growth, epidermal thickness, and fibrillin-rich microfibril deposition (P < 0.01). The 0.3% concentration was significantly better tolerated, with fewer adverse events at P < 0.001.
Past a certain point, skin cannot use any more of it. What is left over does not go into collagen. It goes into irritation. More concentration past that point buys the irritation and nothing else.
The largest results in the published record, the 84% pigmentation reduction and 44% wrinkle reduction from Randhawa (2015), came from 0.1% stabilised retinol applied consistently across that study's 52 weeks. The decisive factor there was consistency, not concentration. A stabilised 0.1% to 0.3% applied nightly beats aggressive high-percentage raw retinol applied sporadically.
The skin does not reward aggression. It rewards precision and time. The right dose, stabilized, delivered consistently. That is the entire protocol.
Synthesis. Randhawa 2015, Draelos 2020, Kong 2016, Mellody 2022THE DELIVERY.
THE DATA.
Vector ONE was formulated from the published record, not from trend cycles. The active is 0.3% encapsulated retinol. That is the concentration where the published comparisons stop showing extra benefit for going higher and start showing extra irritation.
The Kong (2016) trial found 0.1% retinol matched 0.1% retinoic acid on the collagen measured in skin samples. An independent evaluation (Mellody et al., 2022) found 0.3% retinol comparable to 1.0% on new cell growth, epidermal thickening and fibrillin microfibril deposition, while being significantly better tolerated at P < 0.001.
The delivery system matters as much as the percentage. Encapsulation keeps the molecule from oxidising before it reaches viable skin, and shifts it from a surface event to a slow, deep release that puts it where skin can actually use it. In the Draelos (2020) protocol, a stabilised retinol serum produced greater epidermal thickening and more newly formed collagen than the prescription comparator at week 12.
Vector ONE is built around the principles the peer-reviewed evidence points to: a stable molecule, the right concentration, encapsulated delivery, and daily use over months. The outcome data belongs to the cited studies, each of which tested a different proprietary formula. Vector ONE applies those same evidence-based principles in a consumer product.
Randhawa M, et al. J Drugs Dermatol. 2015;14(3):271-280.
Draelos ZD, Peterson RS. J Drugs Dermatol. 2020;19(6):625-631.
Kong R, et al. J Cosmet Dermatol. 2016;15(1):49-57.
Mellody KT, et al. Int J Cosmet Sci. 2022;47:45-57.
